10.4: Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.

An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.

Peptic ulcers can also be classified by location, such as gastric ulcers in the stomach, duodenal ulcers in the small intestine, or esophageal ulcers in the esophagus.

Various factors contribute to PUD, primarily Helicobacter pylori (H. pylori), which may be acquired through ingesting contaminated food and water and person-to-person transmission, mainly through contact with stool, saliva, or vomit. Once ingested, H. pylori generates an enzyme called urease, which converts urea (a compound found naturally in the stomach) to ammonia to reduce stomach acidity, making it a more hospitable environment for the bacterium. After establishing in the gastric mucosa, H. pylori triggers an immune response and releases toxins, resulting in mucosal inflammation and damage.

Next is non-steroidal anti-inflammatory drugs or NSAID-associated PUD. NSAIDs inhibit cyclooxygenase-1 (COX-1) enzymes, which play an important role in the production of prostaglandins. Prostaglandins are essential for maintaining mucosal integrity, mucus and bicarbonate secretion, mucosal blood flow, cell turnover, and repair.

As a result, the inhibition of COX-1 by NSAIDs compromises these defense mechanisms, predisposing the gastric mucosa to be more susceptible to damage from acid and pepsin, which can lead to ulcer formation.

Beyond NSAIDs, other medications like corticosteroids such as prednisolone, and bisphosphonates such as alendronate, potassium chloride, and fluorouracil are implicated in PUD etiology. Smoking, chewing tobacco, and alcohol consumption can further irritate the gastric mucosa and induce acidity.

Peptic ulcer disease is also linked to a rare condition called Zollinger-Ellison syndrome (ZES). ZES involves the formation of tumors, both benign and malignant, in the pancreas and duodenum. These tumors produce excessive quantities of the hormone gastrin, leading to high levels of gastric acid and severe peptic ulcer disease.

Finally, psychological distress can impede the healing of ulcers, while familial tendency may also play a significant role. Individuals with blood type O are more prone to developing peptic ulcers compared to those with blood types A, B, or AB. The increased density of colonization of epithelial cells and heightened inflammatory responses to H. pylori in individuals of blood group O might contribute to an elevated susceptibility to peptic ulceration.

Peptic ulcer disease, or PUD, involves mucosal erosion in the esophagus, stomach, pylorus, or duodenum, appearing as acute or chronic ulcers.

Acute ulcers are short-term, with superficial erosion and minimal inflammation, and they heal quickly after the underlying cause is addressed.

Conversely, chronic ulcers persist for months, potentially penetrating the muscular wall and forming fibrous tissue.

The primary cause of PUD is H.pylori, transmitted via contaminated food, water, or contact with stool, saliva, or vomit.

H.pylori produces urease, converting urea to ammonia to reduce stomach acidity.

Once established, H.pylori triggers an immune response and releases toxins, resulting in mucosal inflammation and damage.

Next, NSAIDs contribute to PUD by inhibiting cyclooxygenase-1, an enzyme vital for prostaglandin production that protects mucosal integrity.

Reduced prostaglandin levels from NSAIDs increase the susceptibility of the gastric mucosa to damage from gastric juices.

Other contributing factors for PUD include alcohol, smoking, stress, Zollinger-Ellison syndrome, and medications like corticosteroids.

• Peptic Ulcer Disease (PUD) - Excavation in mucosal parts such as esophagus, stomach, pylorus, or duodenum.
• Acute ulcer - A short-term, superficial type of PUD with minimal inflammation.
• Chronic ulcer - A persistent form of PUD, which may result in fibrous tissue development.
• Helicobacter pylori (H. pylori) - A key contributor to PUD causing inflammation and damage in the gastric mucosa.
• Non-steroidal Anti-Inflammatory Drugs (NSAIDs) - A significant risk factor for PUD by inhibiting protective prostaglandins production.

• Define PUD - Explain what it is and the different types (e.g., acute and chronic ulcers).
• Contrast Acute vs Chronic Ulcer - Highlight the major differences between these two types (e.g., inflammation extent).
• Explore PUD Causes - Understand key factors contributing to ulcer formation (e.g., H. pylori, NSAIDs).
• Explain the Role of H. pylori - Detail the process of how H. pylori contributes to peptic ulcer development.
• Apply Knowledge of PUD - Discuss potential methods and implications of managing and treating PUD.

• What is PUD and what are its different types?
• How do acute and chronic ulcers differ in their manifestation?
• How does H. pylori contribute to the development of PUD?

• Medical Students - Gain detailed knowledge of PUD, its types, and causes for improved understanding.
• Healthcare Professionals - Foster a comprehensive framework for diagnosis and treatment strategies for PUD.
• Researchers - Explore potential underlying mechanisms and emerging treatment options for PUD.
• General Audience - Gain insight into the complexities of peptic ulcer disease and its management.